Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Jun 30, 2028
  • participants needed
    350
  • sponsor
    ADC Therapeutics S.A.
Updated on 2 September 2021
Investigator
ADC Therapeutics
Primary Contact
Hospital Universitario Fundaci n Jim nez D az (8.2 mi away) Contact
+14 other location
ct scan
platelet count
gonadotropin
lymphoma
rituximab
beta-human chorionic gonadotropin
measurable disease
gilbert's syndrome
human chorionic gonadotropin
oxaliplatin
neutrophil count
gemcitabine
avid
large b-cell lymphoma
high grade b-cell lymphoma
refractory diffuse large b-cell lymphoma
indolent lymphoma

Summary

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Details
Condition Refractory Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Treatment Rituximab, Gemcitabine, Oxaliplatin, Loncastuximab tesirine
Clinical Study IdentifierNCT04384484
SponsorADC Therapeutics S.A.
Last Modified on2 September 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note